The Asia Pacific Pain Patch Market should witness market growth of 5.2% CAGR during the forecast period (2023-2029).
The pain patch provides the benefit of controlled medication distribution over alternative administration techniques because it uses a transdermal route. Generic and brand-name Duragesic medications with transdermal fentanyl patches are both available. Fentanyl is a common medication for treating acute pain since it is an opioid with a rapid onset of pain relief. Fentanyl patches can provide pain relief for up to 72 hours after being applied to the skin.
Patients with a range of primary neurological illnesses are adversely affected by persistent pain, which is a frequent hallmark of many neurodegenerative syndromes. The market for pain relief is being driven by the fact that a number of pathophysiological problems, such as severe trauma to the central nervous system, neuroinflammation, and nerve pain, bring on these disorders. Dementia, Alzheimer's, Parkinson's disease, and other neurological disorders are more prevalent in the elderly. The market for pain patches is anticipated to increase significantly over the next several years due to a sharp growth in the geriatric population.
In India, more than a million new cancer cases are identified each year, and it is predicted that this number will nearly triple over the next 20 years. In late cancer stages, pain occurrence rates are between 70% and 80%. The prevalence of pain was found to be 39.3% after curative treatment, 55.0% (95% CI 45.9-64.2) during anticancer treatment, 66.4% (95% CI 58.1-74.7) in advanced, metastatic, or terminal disease, and 50.7% (95% CI 37.2-64.1) in all cancer stages, with accordance to various studies on cancer pain. It was further seen that 38.0% of cancer patients had moderate-to-severe pain. Therefore, provide growth opportunities for the pain patch market in the region.
The China market dominated the Asia Pacific Pain Patch Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $535.4 million by 2029. The Japan market is estimated to grow a CAGR of 4.5% during (2023-2029). Additionally, The India market would experience a CAGR of 5.8% during (2023-2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Type, the market is segmented into Prescription Medicines and OTC Medicines. Based on Product Type, the market is segmented into Non-Opioid Patches and Opioid Patches. Based on Non-Opioid Patches Type, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Methyl Salicylate, Lidocaine and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include NEXGEL, Inc. Viatris, Inc. Johnson & Johnson. Teva Pharmaceutical Industries Ltd. Grunenthal GmbH. Sorrento Therapeutics, Inc. Hisamitsu Pharmaceutical Co. Inc. Endo International PLC. Purdue Pharma L.P. Amneal Pharmaceuticals, Inc.
The pain patch provides the benefit of controlled medication distribution over alternative administration techniques because it uses a transdermal route. Generic and brand-name Duragesic medications with transdermal fentanyl patches are both available. Fentanyl is a common medication for treating acute pain since it is an opioid with a rapid onset of pain relief. Fentanyl patches can provide pain relief for up to 72 hours after being applied to the skin.
Patients with a range of primary neurological illnesses are adversely affected by persistent pain, which is a frequent hallmark of many neurodegenerative syndromes. The market for pain relief is being driven by the fact that a number of pathophysiological problems, such as severe trauma to the central nervous system, neuroinflammation, and nerve pain, bring on these disorders. Dementia, Alzheimer's, Parkinson's disease, and other neurological disorders are more prevalent in the elderly. The market for pain patches is anticipated to increase significantly over the next several years due to a sharp growth in the geriatric population.
In India, more than a million new cancer cases are identified each year, and it is predicted that this number will nearly triple over the next 20 years. In late cancer stages, pain occurrence rates are between 70% and 80%. The prevalence of pain was found to be 39.3% after curative treatment, 55.0% (95% CI 45.9-64.2) during anticancer treatment, 66.4% (95% CI 58.1-74.7) in advanced, metastatic, or terminal disease, and 50.7% (95% CI 37.2-64.1) in all cancer stages, with accordance to various studies on cancer pain. It was further seen that 38.0% of cancer patients had moderate-to-severe pain. Therefore, provide growth opportunities for the pain patch market in the region.
The China market dominated the Asia Pacific Pain Patch Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $535.4 million by 2029. The Japan market is estimated to grow a CAGR of 4.5% during (2023-2029). Additionally, The India market would experience a CAGR of 5.8% during (2023-2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Type, the market is segmented into Prescription Medicines and OTC Medicines. Based on Product Type, the market is segmented into Non-Opioid Patches and Opioid Patches. Based on Non-Opioid Patches Type, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Methyl Salicylate, Lidocaine and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include NEXGEL, Inc. Viatris, Inc. Johnson & Johnson. Teva Pharmaceutical Industries Ltd. Grunenthal GmbH. Sorrento Therapeutics, Inc. Hisamitsu Pharmaceutical Co. Inc. Endo International PLC. Purdue Pharma L.P. Amneal Pharmaceuticals, Inc.
Scope of the Study
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Type
- Prescription Medicines
- OTC Medicines
By Product Type
- Non-Opioid Patches
- Nonsteroidal Anti-Inflammatory Drugs
- Methyl Salicylate
- Lidocaine
- Others
- Opioid Patches
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- NEXGEL, Inc.
- Viatris, Inc.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Grunenthal GmbH
- Sorrento Therapeutics, Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Endo International PLC
- Purdue Pharma L.P.
- Amneal Pharmaceuticals, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Pain Patch Market, by Distribution Channel
1.4.2 Asia Pacific Pain Patch Market, by Type
1.4.3 Asia Pacific Pain Patch Market, by Product Type
1.4.4 Asia Pacific Pain Patch Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Pain Patch Market by Distribution Channel
3.1 Asia Pacific Drug Stores & Retail Pharmacies Market by Country
3.2 Asia Pacific Hospital Pharmacies Market by Country
3.3 Asia Pacific Online Providers Market by Country
Chapter 4. Asia Pacific Pain Patch Market by Type
4.1 Asia Pacific Prescription Medicines Market by Country
4.2 Asia Pacific OTC Medicines Market by Country
Chapter 5. Asia Pacific Pain Patch Market by Product Type
5.1 Asia Pacific Non-Opioid Patches Market by Country
5.2 Asia Pacific Pain Patch Market by Non-Opioid Patches Type
5.2.1 Asia Pacific Nonsteroidal Anti-Inflammatory Drugs Market by Country
5.2.2 Asia Pacific Methyl Salicylate Market by Country
5.2.3 Asia Pacific Lidocaine Market by Country
5.2.4 Asia Pacific Others Market by Country
5.3 Asia Pacific Opioid Patches Market by Country
Chapter 6. Asia Pacific Pain Patch Market by Country
6.1 China Pain Patch Market
6.1.1 China Pain Patch Market by Distribution Channel
6.1.2 China Pain Patch Market by Type
6.1.3 China Pain Patch Market by Product Type
6.1.3.1 China Pain Patch Market by Non-Opioid Patches Type
6.2 Japan Pain Patch Market
6.2.1 Japan Pain Patch Market by Distribution Channel
6.2.2 Japan Pain Patch Market by Type
6.2.3 Japan Pain Patch Market by Product Type
6.2.3.1 Japan Pain Patch Market by Non-Opioid Patches Type
6.3 India Pain Patch Market
6.3.1 India Pain Patch Market by Distribution Channel
6.3.2 India Pain Patch Market by Type
6.3.3 India Pain Patch Market by Product Type
6.3.3.1 India Pain Patch Market by Non-Opioid Patches Type
6.4 South Korea Pain Patch Market
6.4.1 South Korea Pain Patch Market by Distribution Channel
6.4.2 South Korea Pain Patch Market by Type
6.4.3 South Korea Pain Patch Market by Product Type
6.4.3.1 South Korea Pain Patch Market by Non-Opioid Patches Type
6.5 Singapore Pain Patch Market
6.5.1 Singapore Pain Patch Market by Distribution Channel
6.5.2 Singapore Pain Patch Market by Type
6.5.3 Singapore Pain Patch Market by Product Type
6.5.3.1 Singapore Pain Patch Market by Non-Opioid Patches Type
6.6 Malaysia Pain Patch Market
6.6.1 Malaysia Pain Patch Market by Distribution Channel
6.6.2 Malaysia Pain Patch Market by Type
6.6.3 Malaysia Pain Patch Market by Product Type
6.6.3.1 Malaysia Pain Patch Market by Non-Opioid Patches Type
6.7 Rest of Asia Pacific Pain Patch Market
6.7.1 Rest of Asia Pacific Pain Patch Market by Distribution Channel
6.7.2 Rest of Asia Pacific Pain Patch Market by Type
6.7.3 Rest of Asia Pacific Pain Patch Market by Product Type
6.7.3.1 Rest of Asia Pacific Pain Patch Market by Non-Opioid Patches Type
Chapter 7. Company Profiles
7.1 NEXGEL, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.2 Viatris, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental Analysis
7.2.4 Research & Development Expense
7.3 Johnson & Johnson
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 SWOT Analysis
7.4 Teva Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Grünenthal GmbH
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trials:
7.6 Sorrento Therapeutics, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental Analysis
7.6.4 Research & Development Expenses
7.7 Hisamitsu Pharmaceutical Co. Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Recent strategies and developments:
7.7.3.1 Product Launches and Product Expansions:
7.8 Endo International PLC
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expense
7.9 Purdue Pharma L.P.
7.9.1 Company Overview
7.10. Amneal Pharmaceuticals, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental Analysis
7.10.4 Research & Development Expenses
7.10.5 Recent strategies and developments:
7.10.5.1 Partnerships, Collaborations, and Agreements:
7.10.5.1 Approvals & Trials:
Companies Mentioned
- NEXGEL, Inc.
- Viatris, Inc.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Grunenthal GmbH
- Sorrento Therapeutics, Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Endo International PLC
- Purdue Pharma L.P.
- Amneal Pharmaceuticals, Inc.
Methodology
LOADING...
